Puffy Eye Cream is a prescription therapy used for under eye appearance support.

Patients seeking support for under eye appearance support may qualify after evaluation by a licensed provider.

Yes. Puffy Eye Cream is a compounded prescription topical medication containing triamcinolone acetonide (a topical corticosteroid) and tretinoin (a teratogenic retinoid), both of which require a valid prescription from a licensed healthcare provider. A telehealth consultation, full medical intake, and thorough patient counseling are required before dispensing.

Tretinoin and glycolic acid may cause mild stinging, tingling, or warmth on initial application in patients new to periorbital retinoid or AHA use; this typically resolves with continued use. Mild redness or peeling during the adjustment period may occur. Increased periorbital photosensitivity requires mandatory daily SPF when applying in the morning. Triamcinolone acetonide, with prolonged continuous use, carries a risk of skin atrophy, telangiectasia, or periorbital dermatitis, managed by using the lowest effective dose for the shortest necessary duration. Periorbital corticosteroid use can elevate intraocular pressure; patients should report any changes in vision, eye pressure, or discomfort to their provider and eye care specialist promptly.

Contraindicated in pregnancy, tretinoin is teratogenic. Not appropriate during breastfeeding. Patients with glaucoma, elevated intraocular pressure, or any diagnosed optic nerve pathology must discuss use with their provider and ophthalmologist before initiating. Topical corticosteroids near the eye carry a documented IOP risk with prolonged use. Do not apply to periorbital skin with active bacterial, viral (including herpes simplex / cold sores), or fungal infection. Patients with known retinoid sensitivity, rosacea of the periorbital area, or caffeine allergy should discuss use with their provider.

Concurrent periorbital retinoids (retinol, adapalene) increase irritation risk significantly, do not combine without provider direction. Additional AHAs or BHAs applied to the same area increase barrier disruption risk. Patients on systemic immunosuppressive therapy should ensure all providers are aware of the topical corticosteroid component. Topical immunomodulators (tacrolimus, pimecrolimus) may interact with corticosteroid activity, discuss concurrent use with your provider. Photosensitizing systemic medications require particularly strict daily SPF adherence during tretinoin therapy.

Patients with glaucoma or elevated intraocular pressure must discuss use with their ophthalmologist before initiating. Those with a history of rosacea, periorbital dermatitis, or chronic periorbital skin conditions require individualized assessment. Patients on systemic immunosuppressive therapy or with significant cardiovascular conditions should disclose their full history. Your provider will review your complete medical and ophthalmic history before prescribing.